News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SBP GROUP Receives Approval for Clinical Trial on Innovative Drug TQB3205
SBP GROUP (01177.HK) announced that TQB3205 "Pan-KRAS inhibitor", an innovative drug independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical, had recei...
Reset
Send
The window will close in 5 seconds
SBP GROUP Receives Approval for Clinical Trial on Innovative Drug TQB3205
Close
Recommend
21
Positive
30
Negative
10
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

SBP GROUP (01177.HK)  -0.040 (-0.671%)    Short selling $70.42M; Ratio 19.181%   announced that TQB3205 "Pan-KRAS inhibitor", an innovative drug independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical, had received approval for investigational new drug application from the US Food and Drug Administration for the treatment of advanced malignant tumors.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 16:25.)

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.